Does the media prefer HELP or ARQT?

In the previous week, Cybin had 15 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 25 mentions for Cybin and 10 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.16 beat Cybin's score of 0.54 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cybin 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 7 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, MBX or HELP?

MBX Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio MBX Biosciences N/A N/A -$86.97M -$2.41 N/A Cybin N/A N/A -$148M -$3.02 N/A

Is MBX or HELP more profitable?

MBX Biosciences' return on equity of -26.02% beat Cybin's return on equity. Company Net Margins Return on Equity Return on Assets MBX Biosciences N/A -26.02% -24.94% Cybin N/A -71.78% -64.81%

Does the media refer more to MBX or HELP?

In the previous week, Cybin had 17 more articles in the media than MBX Biosciences. MarketBeat recorded 25 mentions for Cybin and 8 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.74 beat Cybin's score of 0.54 indicating that MBX Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MBX Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor TARS or HELP?

In the previous week, Cybin had 18 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 25 mentions for Cybin and 7 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.53 beat Cybin's score of 0.54 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tarsus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Cybin 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer MOR or HELP?

Cybin has a consensus price target of $48.60, suggesting a potential upside of 251.92%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than MorphoSys. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MorphoSys 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Cybin 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00

Is MOR or HELP more profitable?

Cybin has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Cybin's return on equity of -71.78% beat MorphoSys' return on equity. Company Net Margins Return on Equity Return on Assets MorphoSys -226.79% -694.31% -22.55% Cybin N/A -71.78% -64.81%

Does the media prefer SUPN or HELP?

In the previous week, Cybin had 14 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 25 mentions for Cybin and 11 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.22 beat Cybin's score of 0.54 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Cybin 4 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cybin (HELP) Competitors

$13.81 -0.17 (-1.22%)

As of 01:55 PM Eastern

Compare

HELP vs. ARQT, MBX, TARS, MOR, and SUPN

Should you buy Cybin stock or one of its competitors? Cybin's main competitors and comparable companies include Arcutis Biotherapeutics (ARQT), MBX Biosciences (MBX), Tarsus Pharmaceuticals (TARS), MorphoSys (MOR), and Supernus Pharmaceuticals (SUPN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cybin compare to Arcutis Biotherapeutics?

Cybin (NASDAQ:HELP) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, media sentiment, valuation, profitability and analyst recommendations.

17.9% of Cybin shares are held by institutional investors. 15.0% of Cybin shares are held by company insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, Cybin had 15 more articles in the media than Arcutis Biotherapeutics. MarketBeat recorded 25 mentions for Cybin and 10 mentions for Arcutis Biotherapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.16 beat Cybin's score of 0.54 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cybin	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	7 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics has higher revenue and earnings than Cybin. Cybin is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cybin	N/A	N/A	-$148M	-$3.02	N/A
Arcutis Biotherapeutics	$376.07M	8.48	-$16.14M	$0.21	120.88

Arcutis Biotherapeutics has a net margin of 6.15% compared to Cybin's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cybin	N/A	-71.78%	-64.81%
Arcutis Biotherapeutics	6.15%	15.05%	6.51%

Cybin has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the broader market.

Cybin presently has a consensus target price of $48.60, suggesting a potential upside of 251.92%. Arcutis Biotherapeutics has a consensus target price of $35.57, suggesting a potential upside of 40.13%. Given Cybin's stronger consensus rating and higher probable upside, equities analysts clearly believe Cybin is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Arcutis Biotherapeutics beats Cybin on 10 of the 15 factors compared between the two stocks.

How does Cybin compare to MBX Biosciences?

MBX Biosciences (NASDAQ:MBX) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

MBX Biosciences presently has a consensus target price of $77.00, suggesting a potential upside of 15.16%. Cybin has a consensus target price of $48.60, suggesting a potential upside of 251.92%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than MBX Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MBX Biosciences	2 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.77
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

MBX Biosciences' return on equity of -26.02% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MBX Biosciences	N/A	-26.02%	-24.94%
Cybin	N/A	-71.78%	-64.81%

17.9% of Cybin shares are owned by institutional investors. 31.1% of MBX Biosciences shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

MBX Biosciences is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MBX Biosciences	N/A	N/A	-$86.97M	-$2.41	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

In the previous week, Cybin had 17 more articles in the media than MBX Biosciences. MarketBeat recorded 25 mentions for Cybin and 8 mentions for MBX Biosciences. MBX Biosciences' average media sentiment score of 0.74 beat Cybin's score of 0.54 indicating that MBX Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
MBX Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

MBX Biosciences has a beta of 0.1, suggesting that its share price is 90% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market.

Summary

MBX Biosciences beats Cybin on 8 of the 14 factors compared between the two stocks.

How does Cybin compare to Tarsus Pharmaceuticals?

Tarsus Pharmaceuticals (NASDAQ:TARS) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends, media sentiment and earnings.

Tarsus Pharmaceuticals has a beta of 0.53, suggesting that its stock price is 47% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Tarsus Pharmaceuticals has higher revenue and earnings than Cybin. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tarsus Pharmaceuticals	$451.36M	6.88	-$66.42M	-$1.09	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Cybin has a net margin of 0.00% compared to Tarsus Pharmaceuticals' net margin of -7.67%. Tarsus Pharmaceuticals' return on equity of -13.53% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tarsus Pharmaceuticals	-7.67%	-13.53%	-8.12%
Cybin	N/A	-71.78%	-64.81%

In the previous week, Cybin had 18 more articles in the media than Tarsus Pharmaceuticals. MarketBeat recorded 25 mentions for Cybin and 7 mentions for Tarsus Pharmaceuticals. Tarsus Pharmaceuticals' average media sentiment score of 1.53 beat Cybin's score of 0.54 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tarsus Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Cybin	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. Comparatively, 17.9% of Cybin shares are owned by institutional investors. 9.6% of Tarsus Pharmaceuticals shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Tarsus Pharmaceuticals currently has a consensus target price of $90.50, indicating a potential upside of 27.91%. Cybin has a consensus target price of $48.60, indicating a potential upside of 251.92%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Tarsus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tarsus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.78
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Tarsus Pharmaceuticals and Cybin tied by winning 8 of the 16 factors compared between the two stocks.

How does Cybin compare to MorphoSys?

MorphoSys (NASDAQ:MOR) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

Cybin has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Cybin's return on equity of -71.78% beat MorphoSys' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MorphoSys	-226.79%	-694.31%	-22.55%
Cybin	N/A	-71.78%	-64.81%

In the previous week, Cybin had 25 more articles in the media than MorphoSys. MarketBeat recorded 25 mentions for Cybin and 0 mentions for MorphoSys. Cybin's average media sentiment score of 0.54 beat MorphoSys' score of 0.00 indicating that Cybin is being referred to more favorably in the news media.

Company	Overall Sentiment
MorphoSys	Neutral
Cybin	Positive

Cybin has lower revenue, but higher earnings than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Cybin has a consensus price target of $48.60, suggesting a potential upside of 251.92%. Given Cybin's stronger consensus rating and higher possible upside, analysts plainly believe Cybin is more favorable than MorphoSys.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MorphoSys	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

MorphoSys has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Cybin has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

18.4% of MorphoSys shares are held by institutional investors. Comparatively, 17.9% of Cybin shares are held by institutional investors. 0.1% of MorphoSys shares are held by company insiders. Comparatively, 15.0% of Cybin shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Cybin beats MorphoSys on 11 of the 15 factors compared between the two stocks.

How does Cybin compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Cybin (NASDAQ:HELP) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, profitability, institutional ownership, analyst recommendations, dividends, media sentiment and earnings.

Supernus Pharmaceuticals has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Cybin has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

Supernus Pharmaceuticals presently has a consensus price target of $62.83, suggesting a potential upside of 40.22%. Cybin has a consensus price target of $48.60, suggesting a potential upside of 251.92%. Given Cybin's stronger consensus rating and higher probable upside, analysts plainly believe Cybin is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Cybin	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

17.9% of Cybin shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 15.0% of Cybin shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Cybin had 14 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 25 mentions for Cybin and 11 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.22 beat Cybin's score of 0.54 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cybin	4 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cybin has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Cybin's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Cybin	N/A	-71.78%	-64.81%

Supernus Pharmaceuticals has higher revenue and earnings than Cybin. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Cybin, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$830.44M	3.14	-$38.55M	-$1.92	N/A
Cybin	N/A	N/A	-$148M	-$3.02	N/A

Summary

Supernus Pharmaceuticals and Cybin tied by winning 8 of the 16 factors compared between the two stocks.

Get Cybin News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HELP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HELP vs. The Competition

Export

Metric	Cybin	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01B	$12.41B	$7.29B	$12.73B
Dividend Yield	N/A	2.61%	2.53%	10.79%
P/E Ratio	-4.57	783.01	272.87	24.12
Price / Sales	N/A	761.21	626.49	97.96
Price / Cash	N/A	98.02	78.57	53.12
Price / Book	4.17	12.05	13.14	6.23
Net Income	-$148M	$2.83B	$3.47B	$348.07M
7 Day Performance	17.23%	1.80%	1.11%	0.49%
1 Month Performance	81.23%	6.02%	8.51%	4.66%
1 Year Performance	N/A	8.00%	25.89%	16.65%

Cybin Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HELP Cybin	2.7852 of 5 stars	$13.81 -1.2%	$48.60 +251.9%	N/A	$1.01B	N/A	N/A	50	News Coverage
ARQT Arcutis Biotherapeutics	4.0282 of 5 stars	$26.54 +3.6%	$35.57 +34.0%	+58.4%	$3.29B	$376.07M	126.39	150
MBX MBX Biosciences	2.1397 of 5 stars	$66.52 -2.5%	$75.63 +13.7%	+394.0%	$3.29B	N/A	N/A	N/A
TARS Tarsus Pharmaceuticals	3.7983 of 5 stars	$71.03 +0.6%	$90.50 +27.4%	+26.2%	$3.04B	$451.36M	N/A	50
MOR MorphoSys	N/A	$18.96 flat	N/A	N/A	$2.86B	$238.28M	N/A	730

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HELP) was last updated on 8/26/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cybin (HELP) Competitors

HELP vs. ARQT, MBX, TARS, MOR, and SUPN

How does Cybin compare to Arcutis Biotherapeutics?

Summary

How does Cybin compare to MBX Biosciences?

Summary

How does Cybin compare to Tarsus Pharmaceuticals?

Summary

How does Cybin compare to MorphoSys?

Summary

How does Cybin compare to Supernus Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cybin (HELP) Competitors

HELP vs. ARQT, MBX, TARS, MOR, and SUPN

How does Cybin compare to Arcutis Biotherapeutics?

Do insiders & institutionals hold more shares of HELP or ARQT?

Does the media prefer HELP or ARQT?

Which has preferable earnings and valuation, HELP or ARQT?

Is HELP or ARQT more profitable?

Which has more risk & volatility, HELP or ARQT?

Do analysts prefer HELP or ARQT?

Summary

How does Cybin compare to MBX Biosciences?

Do analysts rate MBX or HELP?

Is MBX or HELP more profitable?

Do institutionals & insiders believe in MBX or HELP?

Which has preferable valuation & earnings, MBX or HELP?

Does the media refer more to MBX or HELP?

Which has more risk and volatility, MBX or HELP?

Summary

How does Cybin compare to Tarsus Pharmaceuticals?

Which has more risk & volatility, TARS or HELP?

Which has higher earnings and valuation, TARS or HELP?

Is TARS or HELP more profitable?

Does the media favor TARS or HELP?

Do insiders & institutionals believe in TARS or HELP?

Do analysts prefer TARS or HELP?

Summary

How does Cybin compare to MorphoSys?

Is MOR or HELP more profitable?

Does the media refer more to MOR or HELP?

Which has higher earnings and valuation, MOR or HELP?

Do analysts prefer MOR or HELP?

Which has more risk & volatility, MOR or HELP?

Do insiders & institutionals hold more shares of MOR or HELP?

Summary

How does Cybin compare to Supernus Pharmaceuticals?

Which has more risk & volatility, SUPN or HELP?

Do analysts recommend SUPN or HELP?

Do insiders and institutionals hold more shares of SUPN or HELP?

Does the media prefer SUPN or HELP?

Is SUPN or HELP more profitable?

Which has preferable valuation & earnings, SUPN or HELP?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HELP vs. The Competition

Cybin Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools